Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 60

Sort by

Sort Order Select

Journal Articles

Inflammatory Waldenström Macroglobulinemia is associated with clonal hematopoiesis: a multicentric cohort

Blood blood.2024025738.

https://doi.org/10.1182/blood.2024025738

Published: 2024

Includes: Supplemental data

Journal Articles

TRAF3 -Inactivated Chronic Lymphocytic Leukemia Cells Show an Enhanced Metabolic Plasticity That Can be Attenuated By Glutaminolysis and Mitochondrial Pyruvate Import Inhibition

Claudia Perez Carretero, Miguel Quijada Álamo, Mariana Tannoury, Léa Dehgane, Alberto Rodríguez-Sánchez, Teresa González, Maria Rocio Benito Sanchez, Elise Chapiro, Ana E. Rodriguez, Florence Nguyen-Khac, Santos A. Susin, Jesús María Hernández-Rivas

Blood (2023) 142 (Supplement 1): 1889.

https://doi.org/10.1182/blood-2023-187054

Published: 2023

Journal Articles

Minimal Residual Disease-Guided Combination of Ibrutinib and Venetoclax Compared to FCR in Untreated Patients with CLL of Intermediate Risk : Interim Results of MRD Kinetics in the Eradic Trial from the Filo Group

Blood (2023) 142 (Supplement 1): 3268.

https://doi.org/10.1182/blood-2023-173341

Published: 2023

Journal Articles

Patients with Chronic Lymphocytic Leukemia Carrying t(14;19) Display a Distinctive Transcriptomic Profile and Adverse Outcome, Which Might be Overcome Continuous Therapy with BTK Inhibitors. an Italian Campus CLL and Eric Study

Andrea Visentin, Enrico Gaffo, Moritz Furstenau, Jennifer A. Woyach, Panagiotis Baliakas, Kerry A Rogers, Cecelia Miller, Claudia Haferlach, Karla Plevova, David Graham Oscier, Zadie Davis, Florence Nguyen Khac, Eleonora Roncaglia, Gian Matteo Rigolin, Anastasia Athanasiadou, Fanny Baran-Marszak, Alberto Valiente, Maria Jose Terol, Pau Abrisqueta, Blanca Espinet, Anna Puiggros, Annalisa Martines, Laura Bonaldi, Francesca Romana Mauro, Lydia Scarfo, Thomas Chatzikonstantinou, Eugen Tausch, Karl Anton Kreuzer, Arnon P. Kater, Francesc Bosch, Michael Doubek, Panayiotis Panayiotidis, Olga Kalashnikova, Federica Frezzato, Monica Facco, Valeria Ruocco, Alessia Buratin, Silvia Orsi, Alessandro Cellini, Francesco Angotzi, Chiara Adele Cavarretta, Ivan Zatta, Andrea Serafin, Robin Foa, Barbara F. Eichhorst, Antonio Cuneo, Kostas Stamatopoulos, Paolo Ghia, Stefania Bortoluzzi, Livio Trentin

Blood (2023) 142 (Supplement 1): 3275.

https://doi.org/10.1182/blood-2023-174569

Published: 2023

Journal Articles

TRAF3 Alterations Identify a Subgroup of Patients with Adverse Clinical Outcome and Induce Metabolic Reprogramming in Chronic Lymphocytic Leukemia

Claudia Pérez Carretero, Miguel Quijada Álamo, Mariana Tannoury, Léa Dehgane, David J. Sanz, Teresa González, Rocio Benito, Elise Chapiro, Maria Hernandez-Sanchez, Ana E. Rodriguez, Florence Nguyen Khac, Santos A. Susin, Jesús María Hernández-Rivas

Blood (2022) 140 (Supplement 1): 4105–4106.

https://doi.org/10.1182/blood-2022-168861

Published: 2022

Journal Articles

A Fixed-Duration Immunochemotherapy Approach Combined with Ibrutinib in CLL Produces Deep and Sustained MRD Responses: 5.5-Year Results from the Icll-07 Filo Trial

Blood (2022) 140 (Supplement 1): 7013–7015.

https://doi.org/10.1182/blood-2022-157963

Published: 2022

Journal Articles

Preliminary Results of the Filo Phase 2 Trial for Untreated Fit Patients with Intermediate Risk Chronic Lymphocytic Leukemia Comparing Ibrutinib Plus Venetoclax (IV) Versus FCR: Results of the Month 15 MRD Evaluation

Blood (2022) 140 (Supplement 1): 7007–7009.

https://doi.org/10.1182/blood-2022-159678

Published: 2022

Journal Articles

Different Prognostic Impact of Recurrent Gene Mutations in IGHV-Mutated and IGHV-Unmutated Chronic Lymphocytic Leukemia: A Retrospective, Multi-Center Cohort Study By Eric, the European Research Initiative on CLL, in Harmony

Larry Mansouri, Birna Thorvaldsdottir, Lesley-Ann Sutton, Manja Meggendorfer, Ferran Nadeu, Christian Brieghel, Helen Parker, Stamatia Laidou, Riccardo Moia, Davide Rossi, Mark Catherwood, Jana Kotaskova, Julio Delgado, Ana E Rodríguez-Vicente, Rocio Benito, Gian Matteo Rigolin, Silvia Bonfiglio, Lydia Scarfo, Mattias Mattsson, Zadie Davis, Ajay Gogia, Lata Rani, Panagiotis Baliakas, Cecilia Jylhä, Aron Skaftason, Inmaculada Rapado, Fatima Miras, Joaquin Martinez-Lopez, Javier de la Serna, Jesús M Hernández Rivas, Patrick Thornton, Maria Jose Larrayoz, María José Calasanz, Zoltán Mátrai, Csaba Bodor, Karin E. Smedby, Blanca Espinet, Anna Puiggros, Ritu Gupta, Lars Bullinger, Francesc Bosch, Bárbara Tazón, Fanny Baran-Marszak, David Oscier, Florence Nguyen-Khac, Thorsten Zenz, María José Terol, Antonio Cuneo, María Hernández-Sánchez, Sarka Pospisilova, Ken I Mills, Gianluca Gaidano, Carsten Utoft Niemann, Elías Campo, Jonathan C Strefford, Paolo Ghia, Kostas Stamatopoulos, Richard Rosenquist

Blood (2021) 138 (Supplement 1): 2617.

https://doi.org/10.1182/blood-2021-150648

Published: 2021

Journal Articles

Preliminary Results of the Filo Phase 2 Trial for Untreated Fit Patients with Intermediate Risk Chronic Lymphocytic Leukemia Comparing Ibrutinib Plus Venetoclax (IV) Versus FCR

Blood (2021) 138 (Supplement 1): 641.

https://doi.org/10.1182/blood-2021-145624

Published: 2021

Journal Articles

A fixed-duration, measurable residual disease–guided approach in CLL: follow-up data from the phase 2 ICLL-07 FILO trial

Blood (2021) 137 (8): 1019–1023.

https://doi.org/10.1182/blood.2020008164

Published: 2021

Includes: Supplemental data

Journal Articles

High frequency of clonal hematopoiesis in Erdheim-Chester disease

Fleur Cohen Aubart, Damien Roos-Weil, Marine Armand, Alice Marceau-Renaut, Jean-François Emile, Nicolas Duployez, Frédéric Charlotte, Stéphanie Poulain, Raphael Lhote, Zofia Hélias-Rodzewicz, Véronique Della-Valle, Olivier Bernard, Karim Maloum, Florence Nguyen-Khac, Jean Donadieu, Zahir Amoura, Omar Abdel-Wahab, Julien Haroche

Blood (2021) 137 (4): 485–492.

https://doi.org/10.1182/blood.2020005101

Published: 2021

Includes: Supplemental data

Journal Articles

Characterizing Specificities of Chronic Lymphoid Leukemia Harboring a BCL2 rearrangement

Blood (2020) 136 (Supplement 1): 29–30.

https://doi.org/10.1182/blood-2020-139210

Published: 2020

Journal Articles

Identification of 2 DNA methylation subtypes of Waldenström macroglobulinemia with plasma and memory B-cell features

Damien Roos-Weil, Brian Giacopelli, Marine Armand, Véronique Della-Valle, Hussein Ghamlouch, Camille Decaudin, Marlen Metzner, Junyan Lu, Magali Le Garff-Tavernier, Véronique Leblond, Paresh Vyas, Thorsten Zenz, Florence Nguyen-Khac, Olivier A. Bernard, Christopher C. Oakes

Blood (2020) 136 (5): 585–595.

https://doi.org/10.1182/blood.2020005081

Published: 2020

Includes: Supplemental data

Journal Articles

Genetic characterization of B-cell prolymphocytic leukemia: a prognostic model involving MYC and TP53

Blood (2019) 134 (21): 1821–1831.

https://doi.org/10.1182/blood.2019001187

Published: 2019

Includes: Supplemental data

Journal Articles

The Broad Spectrum of TP53 Variants in CLL: NGS Analysis of 573 Pathogenic TP53 Variants

Blood (2019) 134 (Supplement_1): 3021.

https://doi.org/10.1182/blood-2019-130907

Published: 2019

Journal Articles

Maintenance of Long-Term Undetectable Minimal Residual Disease after Combination of Ibrutinib with Abbreviated Chemotherapy in the Icll-07 Filo Trial

Blood (2019) 134 (Supplement_1): 3038.

https://doi.org/10.1182/blood-2019-126720

Published: 2019

Journal Articles

Cytogenetic complexity in chronic lymphocytic leukemia: definitions, associations, and clinical impact

Blood (2019) 133 (11): 1205–1216.

https://doi.org/10.1182/blood-2018-09-873083

Published: 2019

Includes: Supplemental data

Journal Articles

p53 Functional Assessment and Correlation with 17p Deletion and/or TP53 Mutation Status: Final Report of the ICLL001 Bomp Trial

Blood (2018) 132 (Supplement 1): 3127.

https://doi.org/10.1182/blood-2018-99-116722

Published: 2018

Journal Articles

Genetic Characterization of B-Cell Prolymphocytic Leukemia (B-PLL): A Hierarchical Prognostic Model Involving MYC and TP53 Abnormalities. on Behalf of the Groupe Francophone De Cytogenetique Hematologique (GFCH) and the French Innovative Leukemia Organization (FILO) Group

Blood (2018) 132 (Supplement 1): 943.

https://doi.org/10.1182/blood-2018-99-115085

Published: 2018

Journal Articles

High Rate of Complete Response (CR) with Undetectable Bone Marrow Minimal Residual Disease (MRD) after Chemo-Sparing and MRD-Driven Strategy for Untreated Fit CLL Patients: Final Results of the Icll 07 Filo Trial

Blood (2018) 132 (Supplement 1): 1858.

https://doi.org/10.1182/blood-2018-99-111977

Published: 2018

NARROW

Inflammatory Waldenström Macroglobulinemia is associated with clonal hematopoiesis: a multicentric cohort

TRAF3 -Inactivated Chronic Lymphocytic Leukemia Cells Show an Enhanced Metabolic Plasticity That Can be Attenuated By Glutaminolysis and Mitochondrial Pyruvate Import Inhibition

Minimal Residual Disease-Guided Combination of Ibrutinib and Venetoclax Compared to FCR in Untreated Patients with CLL of Intermediate Risk : Interim Results of MRD Kinetics in the Eradic Trial from the Filo Group

Patients with Chronic Lymphocytic Leukemia Carrying t(14;19) Display a Distinctive Transcriptomic Profile and Adverse Outcome, Which Might be Overcome Continuous Therapy with BTK Inhibitors. an Italian Campus CLL and Eric Study

TRAF3 Alterations Identify a Subgroup of Patients with Adverse Clinical Outcome and Induce Metabolic Reprogramming in Chronic Lymphocytic Leukemia

A Fixed-Duration Immunochemotherapy Approach Combined with Ibrutinib in CLL Produces Deep and Sustained MRD Responses: 5.5-Year Results from the Icll-07 Filo Trial

Preliminary Results of the Filo Phase 2 Trial for Untreated Fit Patients with Intermediate Risk Chronic Lymphocytic Leukemia Comparing Ibrutinib Plus Venetoclax (IV) Versus FCR: Results of the Month 15 MRD Evaluation

Different Prognostic Impact of Recurrent Gene Mutations in IGHV-Mutated and IGHV-Unmutated Chronic Lymphocytic Leukemia: A Retrospective, Multi-Center Cohort Study By Eric, the European Research Initiative on CLL, in Harmony

Preliminary Results of the Filo Phase 2 Trial for Untreated Fit Patients with Intermediate Risk Chronic Lymphocytic Leukemia Comparing Ibrutinib Plus Venetoclax (IV) Versus FCR

A fixed-duration, measurable residual disease–guided approach in CLL: follow-up data from the phase 2 ICLL-07 FILO trial

High frequency of clonal hematopoiesis in Erdheim-Chester disease

Characterizing Specificities of Chronic Lymphoid Leukemia Harboring a BCL2 rearrangement

Identification of 2 DNA methylation subtypes of Waldenström macroglobulinemia with plasma and memory B-cell features

Genetic characterization of B-cell prolymphocytic leukemia: a prognostic model involving MYC and TP53

The Broad Spectrum of TP53 Variants in CLL: NGS Analysis of 573 Pathogenic TP53 Variants

Maintenance of Long-Term Undetectable Minimal Residual Disease after Combination of Ibrutinib with Abbreviated Chemotherapy in the Icll-07 Filo Trial

Cytogenetic complexity in chronic lymphocytic leukemia: definitions, associations, and clinical impact

p53 Functional Assessment and Correlation with 17p Deletion and/or TP53 Mutation Status: Final Report of the ICLL001 Bomp Trial

Genetic Characterization of B-Cell Prolymphocytic Leukemia (B-PLL): A Hierarchical Prognostic Model Involving MYC and TP53 Abnormalities. on Behalf of the Groupe Francophone De Cytogenetique Hematologique (GFCH) and the French Innovative Leukemia Organization (FILO) Group

High Rate of Complete Response (CR) with Undetectable Bone Marrow Minimal Residual Disease (MRD) after Chemo-Sparing and MRD-Driven Strategy for Untreated Fit CLL Patients: Final Results of the Icll 07 Filo Trial

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only